|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 欢迎人工智能临床研究的新指南显示文摘目前,人工智能在医学领域的临床试验数量十分有限,因此相关研究方案和报告的首份指南的出现恰逢其时。更好的研究方案设计,以及一致、完整的数据展示将极大地促进对这些试验的理解和验证,并促进该领域向前发展。 | 熊云云(译) 李子孝(译) 丁玲玲(译) 谷鸿秋(译) 王春娟(译) 王春雪(译) 王拥军(译) TOPOL E J | 2020 | 中国卒中杂志2020，15，11： | 7 |
| 2 | Tissue factor,the emerging link between inflammation,thrombosis,and remodeling 显示文摘 | PENN M S TOPOL E J | 2001 | Cir Res2001，89，1： | 2 |
| 3 | Pharmacological Approaches for the Prevention of Restenosis after Percutaneous Coronary Intervention显示文摘 | Lefkovit J Topol E J | 1997 | Prog Cardiovasc Dis1997，40，2： | 1 |
| 4 | C-Reactive Protein:a'golden marker' for inflammation and coronary artery disease显示文摘 | Patel V B Robbins M A Topol E J | 2001 | Cleve Clin J Med2001，68，6： | 1 |
| 5 | Comparison of long-term survival following non-Q wave creatine kinase elevation after percutaneous coronary intervention in patients discharged on a beta blocker versus those not so treated显示文摘 | ELLIS S G SCHNEIDER J P TOPOL E J | 2002 | Am J Cardiol2002，89，： | 1 |
| 6 | Patient stratification and its predictive valve for cardiac events显示文摘 | Topol E | 1998 | Eur Heart J1998，19，： | 1 |
| 7 | Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction显示文摘 | GRINES CL TOPOL E J O'NEILL WW | 1995 | Circulation1995，91，： | 1 |
| 8 | Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention显示文摘 | LEFKOVITS J TOPOL E J | 1997 | Prog Cardiovasc Dis1997，40，： | 1 |
| 9 | Coronary disease:acute myocardial infarction thrombolysis显示文摘 | TOPOL E J | 2000 | Heart2000，83，2： | 1 |
| 10 | Recognition of the importance of embolization in atherosclerotic vascular disease 显示文摘 | Topol E J Yadav JS | 2000 | Circulation2000，101，： | 1 |
| 11 | Effect of direct-to-consumer genomewide proling to assess disease risk显示文摘 | Bloss C S Schork N J Topol E J | 2011 | N Engl J Med2011，364，6： | 1 |
| 12 | Tissue factor,the emerging link between inflammation,thrombosis,and vascular remodeling显示文摘 | PENN M S TOPOL E J | 2001 | Cir Res2001，89，1： | 1 |
| 13 | Bleeding complications with the chimeric antibody to platelet glycoproteinⅡb/Ⅲa intergrin in patientes un-dergoing percutancous coronary intervention显示文摘 | AGUIRRE F V TOPOL E I FERGUSON J J et a1 | 1995 | Circula-tion1995，91，12： | 1 |
| 14 | Platelet Glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? 显示文摘 | QUINN M J PLOW E F Topol E J | 2002 | Circulation2002，106，3： | 1 |
| 15 | Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease显示文摘 | BHATT D L TOPOL E J | 2000 | Med Clin North Am2000，84，1： | 1 |
| 16 | Link between the angiographic substudy and mortality outcome in a large randomized trial of myocardial reperfusion:Importance of early and complete artery reperfusion显示文摘 | SIMES RJ TOPOL E J HOLMES DR | 1995 | Circulation1995，91，7： | 1 |
| 17 | Recognition of the importance of embolization in atherosclerotic vascular disease显示文摘 | Topol E J Yadav JS | 2000 | Circulation2000，101，5： | 1 |
| 18 | Local drug delivery systems and pevention of restenosis显示文摘 | Brieger D Topol E | 1997 | Cardiovas Res1997，35，3： | 1 |
| 19 | Our preoccupation with coronary luminology:the dissociation between clinical and angiographic findings in ischemic heart disease显示文摘 | Topol E Nissen S | 1995 | Circulation1995，92，8： | 1 |
| 20 | Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial显示文摘 | TOPOL E J GUSTO V Investigators | 2001 | Lancet2001，357，9272： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员